Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia

References

• Johannessen JO. Review: lifetime prevalence of schizophrenia and related disorders is about 5.5 per 1000, but there is significant variation between regions. Evid Based Ment Health 2003;6:74
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision, DSM-IV-TR. 4th edn. Washington, DC: American Psychiatric Association; 2000:297-313
   Google Scholar
• Bellack AS, Green MF, Cook JA, et al. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull 2007;33:805-22
   PubMed Web of Science ®Google Scholar
• Barrowclough C, Tarrier N. Social function in schizophrenic patients. I. The effects of expressed emotion and family intervention. Soc Psychiatry Psychiatr Epidemiol 1990;25:125-9
   PubMed Web of Science ®Google Scholar
• Yager JA, Ehmann TS. Untangling social function and social cognition: a review of concepts and measurement. Psychiatry 2006;69:47-68
   PubMed Web of Science ®Google Scholar
• Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007;116:403-18
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
   PubMed Web of Science ®Google Scholar
• Kane J, Kramer M, Ford L, et al. Treatment of schizophrenia with paliperidone extended release: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
   PubMed Web of Science ®Google Scholar
• Marder S, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo controlled study. Biol Psychiatry 2007;62:1363-70
   PubMed Web of Science ®Google Scholar
• Doyle M, Flanagan S, Browne S, et al. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr Scand 1999;99:466-72
   PubMed Web of Science ®Google Scholar
• Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry 1997;154:99-105
   PubMed Web of Science ®Google Scholar
• Perring C, Twigg, J, Atkin, K. Families Caring for People Diagnosed as Mentally Ill: The Literature Re-Examined. London, UK: University of York Social Policy Research Unit, 1990
   Google Scholar
• Schene AH, van Wijngaarden B, Koeter MW. Family caregiving in schizophrenia: domains and distress. Schizophr Bull 1998;24:609-18
   PubMed Web of Science ®Google Scholar
• Bindman J, Beck A, Thornicroft G, et al. Psychiatric patients at greatest risk and in greatest need. Impact of the Supervision Register Policy. Br J Psychiatry 2000;177:33-7
   PubMed Web of Science ®Google Scholar
• Nasrallah H, Morosini PL, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res 2008;161:213-24
   PubMed Web of Science ®Google Scholar
• Kasper S, Rosillon D, Duchesnec I; on behalf of the RODOS Investigator Group. Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:179-87
   Google Scholar
• Burns T, Christova L, Cooper S, et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006;113:126-34
   PubMed Web of Science ®Google Scholar
• Meltzer H, Kramer M, Gassmann-Mayer C, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. Int J Neuropsychopharmacol 2006;9 (Suppl 1): Abstr P02.22
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health, 1976
   Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46
   PubMed Web of Science ®Google Scholar
• Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-8
   PubMed Web of Science ®Google Scholar
• Nunally JC, Bernstein IH. Psychometric Theory, 3rd edn. New York, NY: McGraw-Hill, 1994
   Google Scholar
• Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993;2:221-6
   PubMed Web of Science ®Google Scholar
• Lydick E. Approaches to the interpretation of quality-of-life scales. Med Care 2000;38 (9 Suppl):II180-3
   PubMed Web of Science ®Google Scholar
• Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:73-96
   PubMedGoogle Scholar
• Wyrwich KW. Minimal important difference thresholds and the standard error of measurement: is there a connection? J Biopharm Stat 2004;14:97-110
   PubMedGoogle Scholar
• Hays RD, Brodsky M, Johnston MF, et al. Evaluating the statistical significance of health-related quality-of-life change in individual patients. Eval Health Prof 2005;28:160-71
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005;14:285-95
   PubMed Web of Science ®Google Scholar
• Cramer J, Rosenheck R, Xu W, et al. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 2001;27:227-34
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res 2005;79:231-8
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988:19-27
   Google Scholar
• American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia: second edition. 2004. Available at: http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2ePG_05-15-06. [Last accessed 29 March 2008]
   Google Scholar
• Wiersma D, Wanderling J, Dragomirecka E, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med 2000;30:1155-67
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. January, 2004. Available at: http://www.emea.europa.eu/pdfs/human/ewp/13939104en.pdf. [Last accessed 29 March 2008]
   Google Scholar
• Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Draft distributed February, 2006. Available at: http://www.fda.gov/cder/guidance/5460dft.pdf. [Last accessed 29 March 2008]
   Google Scholar